Why is there not more talk about CBD? It is currently being tested (phase 2) @Yale and in Germany.
There has been a lot of buzz around this compound yet I can’t find a lot people who have given it a try. Maybe because purified CBD is not readily available (only CBD with thc and other cannabinoids which can have unwanted side-effects even in very low dose).
What should I make of this compound as I am thinking of going in as a phase-2-subject?
I use it every day. I’m lucky to live in a state its legal in. Not many places its available in.
The only pharma company doing research I know of is echo pharma.
http://www.echo-pharma.com/en/products-and-pipeline/pipeline/schizophrenia/
It should be legal in all US states.
I need to save up some money to buy some quality CBD oil.
I have tried charlottes web cbd oil but found the presence of thc (1mg thc/25mg cbd) did make me more disorganized.
What is ur protocol?
And gwpharma in the UK.
I think they’ve given up. Not sure though.
I vape the CBD oil.
I have tried vaping. 9%CBD <0.4%THC. The effects that I felt seemed to be thc-dominant.
What am I supposed to feel when vaping?
Schizophrenia
Schizophrenia is a chronic disease that manifests through disturbances of perception, thought, cognition, emotion, motivation and motor activity. Over a lifetime, about 1% of the population will develop schizophrenia.
Our product, GWP42003, has shown notable anti-psychotic effects in accepted pre-clinical models of schizophrenia and importantly has also demonstrated the ability to reduce the characteristic movement disorders induced by currently available anti-psychotic agents.
In September 2015, we announced top line results from an exploratory Phase 2a placebo-controlled clinical trial of CBD in 88 patients with schizophrenia who had previously failed to respond adequately to first line anti-psychotic medications. We believe that the signals demonstrated in this trial, together with the safety profile, provide us with the prospect of new and distinct cannabinoid neuropsychiatric product pipeline opportunity, as the mechanism of CBD does not appear to rely on the dopamine D2 receptor augmentation of standard antipsychotics.
We are now analyzing the data to fully understand the appropriate next steps regarding product development in schizophrenia with future research likely focused on pediatric orphan neuropsychiatric indications.
Yeah , they might be just focusing on the pediatric market. If at all.
No sorry I messed up. I repasted the bit about schizophrenia. See^^
And from checking their website a bit more it looks like they are still considering phase 3. Well nothing indicates that they are not.
I tried a 40:1 CBD:THC product which I could obtain legally here in California, at the suggested dose I did not notice any effects so I ended up using a huge amount to obtain effects, it was like normal weed but more subdued but I still got really paranoid and detrimental effects so I had to discontinue use. Like you say it is a shame there is not any pure CBD available I would probably give it a try.
I get this at my headshop. It’s no thc.
